Nextplat Stock Earnings Reports

NextPlat reported Q1 2026 results highlighting a successful turnaround with strong margin improvement and reduced operating losses. Total net revenue was ~$10M (down YoY due to restructuring), with healthcare representing ~68% of revenue (~$7M) and e-commerce ~$3.2M. Consolidated gross profit was ~$3.4M and gross margin expanded to ~35% (vs ~21% a year ago). Operating loss improved to ~$1.1M from ~$2.1M a year earlier; healthcare segment generated positive operating income (~$24k) for the quarter. Key operational drivers: focus on higher-margin 340B contracts and medication fulfillment (average ~7,500 prescriptions/month to contract facilities in Florida), optimization of payer/product mix, and Medicare Maximum Fair Price reimbursement changes that aided margins. Management completed a reverse split to regain Nasdaq compliance, established an ATM program for strategic flexibility (no immediate plans to use it), ended the quarter with ~ $11M cash and no meaningful debt, and is expanding healthcare operations nationwide (including an e-commerce launch planned before end of Q2 and a newly created nationwide fulfillment partnership). Management expects continued margin-driven progress, further revenue contributions from newly onboarded 340B customers starting in Q3, disciplined expense control, and potential M&A/joint-venture-driven scale to support long-term profitability in H2 2026.